Potential Benefits of Second-Generation Human Papillomavirus Vaccines

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Kiatpongsan, Sorapop ^a,b   Campos, Nicole Gastineau ^c   Kim, Jane J ^c  

^a HARVARD UNIVERSITY   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CALIBRATION; CANCER RISK; CROSS REACTION; DRUG UTILIZATION; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; KENYA; MIXED INFECTION; PAPILLOMAVIRUS INFECTION; RISK REDUCTION; SIMULATION; UGANDA; UTERINE CERVIX CANCER;

COINFECTION; CROSS PROTECTION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; KENYA; PAPILLOMAVIRUS VACCINES; UGANDA; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84868673869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048426     Document Type: Article

References (26)

1. Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, et al. (2012) Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 130: 2672-2684.
2. Armstrong EP, (2010) Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 16: 217-230.
3. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G, (2009) Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 27: 127-147.
4. Holmes J, Hemmett L, Garfield S, (2005) The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ 6: 30-37.
5. Techakehakij W, Feldman RD, (2008) Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 26: 6258-6265.
6. Schiller JT, Nardelli-Haefliger D, (2006) Chapter 17: Second generation HPV vaccines to prevent cervical cancer. Vaccine 24 (Suppl 3):: S3/147-153.
7. Stanley M, (2010) Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 23: 70-75.
8. ClinicalTrials.Gov website. Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001). Available: http://clinicaltrials.gov/ct2/show/NCT00543543. Accessed 2012 Oct 1.
9. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ, (2008) Modeling cervical cancer prevention in developed countries. Vaccine 26 (Suppl 10):: K76-86.
10. Regan DG, Philp DJ, Hocking JS, Law MG, (2007) Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 4: 147-163.
11. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, et al. (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96: 604-615.
12. Kim SY, Sweet S, Chang J, Goldie SJ, (2011) Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis 11: 174.
13. Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, et al. (2011) Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med 9: 54.
14. Sroczynski G, Schnell-Inderst P, Muhlberger N, Lang K, Aidelsburger P, et al. (2010) Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess 6: Doc05.
15. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S, (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124: 1626-1636.
16. Clifford GM, Smith JS, Aguado T, Franceschi S, (2003) Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89: 101-105.
17. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, et al. (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802.
18. De Vuyst H, Franceschi S, (2007) Human papillomavirus vaccines in HIV-positive men and women. Curr Opin Oncol 19: 470-475.
19. Odida M, de Sanjose S, Quint W, Bosch XF, Klaustermeier J, et al. (2008) Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis 8: 85.
20. De Vuyst H, Gichangi P, Estambale B, Njuguna E, Franceschi S, et al. (2008) Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer 122: 244-246.
21. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
22. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
23. Herrero R, (2009) Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 199: 919-922.
24. WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer website. HPV type distribution in invasive cervical cancer in Asia, Africa, Americas, Europe and Oceania continents. Available: http://www.who.int/hpvcentre/en/. Accessed 2012 Oct 1.
25. Laz TH, Rahman M, Berenson AB, (2012) An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010. Vaccine 30: 3534-3540.
26. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE, (2011) The cost-effectiveness of male HPV vaccination in the United States. Vaccine 29: 8443-8450.